Circulating Exosomal Gastric Cancer–Associated Long Noncoding RNA1 as a Biomarker for Early Detection and Monitoring Progression of Gastric Cancer

Abstract

IMPORTANCE The gastric cancer (GC)-associated long noncoding RNA1 (lncRNA-GC1) plays an important role in gastric carcinogenesis. However, exosomal lncRNA-GC1 and its potential role in GC are poorly understood. OBJECTIVE To evaluate the diagnostic value of circulating exosomal lncRNA-GC1 for early detection and monitoring progression of GC. DESIGN, SETTING, AND PARTICIPANTS We performed a multiphase investigation of circulating exosomal lncRNA-GC1 for early detection of GC involving consecutive patients with GC (n = 522), patients with gastric precancerous lesions (n = 85), and healthy donor individuals (HDs; n = 219) from December 2016 to February 2019 at Chinese People's Liberation Army General Hospital, China. LncRNA-GC1 was measured by reverse transcription-polymerase chain reaction by independent researchers who had no access to patients' information. Receiver operating characteristic curves were used to calculate diagnostic efficiency in comparison between lncRNA-GC1 and 3 traditional biomarkers (carcinoembryonic antigen [CEA], cancer antigen 72-4 [CA72-4], and CA19-9). MAIN OUTCOMES AND MEASURES Assessment of diagnostic efficiency on the basis of area under curve (AUC), specificity, and sensitivity. RESULTS Of the 826 patients included in the study, 508 were men (61.5%), and the median age of all patients was 60 years (range, 28-82 years). In the test phase, lncRNA-GC1 achieved better diagnostic performance than the standard biomarkers CEA, CA72-4, and CA19-9 (AUC = 0.9033) for distinguishing between the patients with GC and HDs. Additionally, exosomal lncRNA-GC1 levels were significantly higher in culture media from GC cells compared with those of normal gastric epithelial cells (t = 5.310; P = .002). In the verification phase, lncRNA-GC1 retained its diagnostic efficiency in discriminating patients with GC from those with gastric precancerous lesions as well from HDs. Moreover, lncRNA-GC1 exhibited a higher AUC compared with those of CEA, CA72-4, and CA19-9 for early detection of GC with sufficient specificity and sensitivity, especially for patients with GC with negative standard biomarkers. Moreover, the levels of circulating exosomal lncRNA-GC1 were significantly associated with GC from early to advanced stages (HD vs stage I, t = 20.98; P < .001; stage I vs stage II, t = 2.787; P = .006; stage II vs stage III, t = 4.471; P < .001; stage III vs stage IV, t = 1.023; P = .30), independent of pathological grading and Lauren classification (pathological grading: HD vs G1, t = 21.09; P < .001; G1 vs G2, t = 0.3718; P = .71; G2 vs G3, t = 0.3598; P = .72; Lauren classification: t = 24.81; P <.001). In the supplemental phase, the levels of circulating exosomal lncRNA-GC1 were consistent with those in GC tissues and cells and were higher compared with those in normal tissues and cells. Furthermore, the levels of circulating lncRNA-GC1 were unchanged after exosomes were treated with RNase and remained constant after prolonged exposure to room temperature or after repeated freezing and thawing (t = 1.443; P = ....

EGR1‐mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer

“…Massive studies have elucidated that lncRNAs play important roles in the pathogenesis and progression of multiple cancers 10,21,23,26 . Currently, lncRNAs show great potential as targets and combined targeting of dysregulated lncRNAs may become a promising option for future cancer therapeutics 35,36 . Therefore, it is of great significance to enlarge the identification of lncRNAs and their underlying mechanisms, thereby facilitating the progress of lncRNA‐based treatments.…”

Extracellular Vesicles as a Novel Liquid Biopsy-Based Diagnosis for the Central Nervous System, Head and Neck, Lung, and Gastrointestinal Cancers: Current and Future Perspectives

“…Again, the diagnostic potential of these EV biomarkers was higher than CEA or CA19.9. In a larger study by Guo et al [ 157 ], involving 826 individuals, lncRNA-GC1 was found to discriminate GC in early GC patients, in healthy individuals with or without H. Pylori infection, and individuals with pre-malignant gastric lesions (intestinal metaplasia and atrophic gastritis) ( Table 6 ). Although endoscopy is required for a conclusive diagnosis, it is conceivable to assume that the combination of standard biomarkers and EV-specific cargoes may be useful to better select patients requiring invasive diagnostic procedures.…”

Potential Therapeutic Targeting of lncRNAs in Cholesterol Homeostasis

“…For example, prostate-specific lncRNA prostate cancer antigen 3 (PCA3) levels have been suggested as a diagnostic biomarker of prostate cancer ( 98 ). Other lncRNAs used as biomarkers include circulating plasma H19 for gastric cancer ( 99 ), HULC in hepatocellular carcinoma ( 100 ), circulating lncRNA in SNHG11 colorectal cancer ( 101 ), circulating exosomal lncRNA-GC1 in gastric cancer ( 102 ), and HOTAIR in various cancers, including breast, colorectal, liver, gastric, lung, and thyroid ( 103 – 107 ).…”